Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT03739619 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03739619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03739619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Lead sponsor
Emory University
Phase
Phase 1/2
Overall status
Completed
Start date
November 26, 2018
Completion date
April 30, 2025
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma, hodgkin lymphoma, recurrent hodgkin lymphoma, refractory hodgkin lymphoma